Next Article in Journal
Baseline Splenic Volume Outweighs Immuno-Modulated Size Changes with Regard to Survival Outcome in Patients with Hepatocellular Carcinoma under Immunotherapy
Next Article in Special Issue
Using Patient-Derived Xenograft (PDX) Models as a ‘Black Box’ to Identify More Applicable Patients for ADP-Ribose Polymerase Inhibitor (PARPi) Treatment in Ovarian Cancer: Searching for Novel Molecular and Clinical Biomarkers and Performing a Prospective Preclinical Trial
Previous Article in Journal
Early Prediction of Planning Adaptation Requirement Indication Due to Volumetric Alterations in Head and Neck Cancer Radiotherapy: A Machine Learning Approach
Previous Article in Special Issue
PARP Inhibitors Resistance: Mechanisms and Perspectives
 
 
Article

Article Versions Notes

Cancers 2022, 14(15), 3572; https://doi.org/10.3390/cancers14153572
Action Date Notes Link
article xml file uploaded 22 July 2022 13:08 CEST Original file -
article xml uploaded. 22 July 2022 13:08 CEST Update https://www.mdpi.com/2072-6694/14/15/3572/xml
article pdf uploaded. 22 July 2022 13:08 CEST Version of Record https://www.mdpi.com/2072-6694/14/15/3572/pdf
article supplementary file uploaded. 22 July 2022 13:08 CEST - https://www.mdpi.com/2072-6694/14/15/3572#supplementary
article html file updated 22 July 2022 13:09 CEST Original file -
article html file updated 13 August 2022 03:09 CEST Update https://www.mdpi.com/2072-6694/14/15/3572/html
Back to TopTop